Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Economic information and modeling report

Modeling overview

60 evidence topics · 33 sources

Summary: published cost-effectiveness analyses of AMT-130 and of disease-modifying therapy in Huntington's disease

  • A cost-effectiveness analysis of tominersen and AMT-130 in Huntington's disease (HD) used a Markov model with four health states (early, middle, late, and death) from a modified societal perspective, with a 1-year cycle length, a 3% annual discount rate, and 30 annual cycles. All patients entered in the early stage, and utilities for both treatments were assumed equal to standard of care because trial-based utility data are not yet available. Lacking established cost data, the authors assumed the cost of AMT-130 to be the list price of Zolgensma, applied a 15% payer discount to estimate a one-time dose at $1,806,250, and used an AMT-130 administration cost of $23,516. Compared with standard of care, AMT-130 increased costs by $1.49 million and QALYs by 5.23, for an incremental cost-effectiveness ratio of $285,703 per QALY gained; the ratio for tominersen was $2.28 million per QALY gained. The authors applied a willingness-to-pay threshold of $500,000/QALY gained because HD is a rare disease. AMT-130 had an 80% probability of being cost-effective at $350,000/QALY gained, 30% at $250,000 per QALY gained, and 0% for both treatments at $100,000–150,000 per QALY gained. Adding the value of hope changed the AMT-130 ratio to $236,540 per QALY gained. The ratios were most sensitive to drug costs and to early and middle-stage utilities, and the authors state that the model relied heavily on the assumption of sustained benefit beyond the data.
  • A U.S. decision-modeling framework for future disease-modifying treatments estimated lifetime costs of HD of $508,200 for the PFD population, $1.15 million for SF1 individuals, and $1.07 million for SF2 individuals; the authors did not assign a price to a disease-modifying treatment because the treatments under development vary in mechanism, route of administration, and once versus recurrent therapy.
  • A United Kingdom model fitted a continuous-time hidden Markov disease progression model with five states to Enroll-HD data, and its cost modelling showed that indirect costs such as state benefits and lost gross domestic product contribution could drive the societal cost of HD over health and social care costs.
  • In a PTC Therapeutics-funded analysis of eladocagene exuparvovec-tneq, the administration cost, a proxy for the cost of the stereotactic procedure, was $106,030 and the incremental cost per QALY ranged from $199,007–$224,104.

Summary: ICER assessment of AMT-130 and its model analysis plan

  • Scope and timeline: the Institute for Clinical and Economic Review (ICER) is assessing the comparative clinical effectiveness and value of AMT-130 for Huntington's disease, with public discussion at a Midwest CEPAC meeting in March 2027. The population of focus is adults with early symptomatic Huntington's disease, the comparator is usual symptomatic care, and the draft scope set publication of the model analysis plan for November 16, 2026. The revised scope proposes assessing AMT-130 under an adaptation of the ICER Value Framework for single and short-term therapies, with analyses from the health care system perspective and the modified societal perspective and outcomes of years of independent living gained, life-years gained, QALYs gained, and evLYs. The revised scope states that uniQure had been unwilling to speak with ICER and, at uniQure's request, that uniQure did not participate in the process and did not review or approve the methodology, findings, or conclusions.
  • Framework: under ICER's single and short-term therapy adaptations, analyses include a 50/50 shared savings model, in which 50% of lifetime health system cost offsets are assigned to the health system, and a cost-offset cap model, in which cost offsets are capped at $150,000 per year, the top of the ICER range for value-based pricing for an additional QALY. A threshold analysis for the durability of effect estimates the duration of benefit AMT-130 would need to reach standard cost-effectiveness thresholds.
  • Structure: the model analysis plan describes a cohort Markov model comparing AMT-130 added onto usual symptomatic care with usual symptomatic care alone over a lifetime horizon, from a health care sector perspective in the base case, with a one-year cycle and costs and outcomes discounted at 3% per year. Health states follow Shoulson and Fahn staging by Total Functional Capacity (TFC): stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 (TFC 1-2), and stage 5 (TFC 0). All patients enter in stage 1, based on a baseline TFC of 12.1 in the pivotal trial's primary analysis, and the target population is adults with early manifest HD, with inputs from the high-dose arm.
  • Natural history and treatment effect: on usual symptomatic care, TFC declines at a constant rate of -0.23 TFC/year, from a linear regression of Enroll-HD cohort B TFC scores at baseline, 12, 24, 36 and 48 months. On AMT-130, progression follows the observed TFC trajectory up to 48 months; afterwards, the base case applies the usual care decline rate reduced by 61%, the treatment effect on TFC at 48 months, or rates estimated by the clinical team, and durability remains over the lifetime. A scenario applies a 44% slowing of TFC progression based on cUHDRS, and other scenarios address natural history, durability, waning, outcome-based payment arrangements, and a premanifest population.
  • Other inputs: mortality follows U.S. general population life tables with stage-specific excess mortality (0.000 in SF stage 1 to 0.146 in SF stage 5); utilities range from 0.78 in SF stage 1 to 0.22 in SF stages 4 and 5; costs are in 2025 US dollars. Peri-operative and treatment-related serious adverse events are applied as one-time costs at rates of 16.4% ($10,645) and 19.2% ($19,501). All-cause background costs from Medicaid claims are $28,454 in early, $69,016 in middle, and $118,889 in late HD, and indirect costs are $85,656, $133,500, and $112,816.
  • Price, outcomes, and budget impact: the placeholder price is $2,600,000, the midpoint of analyst estimates from $1,700,000 to $3,500,000, and the administration price of $24,138.83 is based on the estimates of an earlier AMT-130 model. Outcomes include years of independent life and years free of full-time care; probabilistic sensitivity analysis uses 1,000 simulations, and threshold analyses for drug costs span $50,000, $100,000, $150,000, and $200,000 per QALY and evLY gained. Budget impact is estimated over a five-year time horizon for 25,811 eligible patients, of whom 20% initiate treatment each year (5,162 patients per year), against a threshold of approximately $709 million per year.

Summary: price basis, other gene therapy prices, and payment models

  • In June, Leerink analysts estimated a U.S. price of $1.7 million and worldwide sales of $2.5 billion in 2030 if AMT-130 is approved. The ICER placeholder price of $2,600,000 rests on estimates from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics. uniQure's annual report states that third-party payers and ICER increasingly challenge prices and examine budget impact and cost-effectiveness, and that the CMS GENEROUS Model requires rebates aligned with Most Favored Nation pricing to participating state Medicaid programs.
  • Prices of other products: Zolgensma, a one-time treatment, $2.125 million list price ($425,000 per year for five years); the gene therapy Hemgenix, $3.5 million list price, for which ICER had used a $4 million placeholder price and found a Health Benefit Price Benchmark of $2.93 million to $2.96 million; Roctavian, $2.9 million wholesale acquisition cost; the gene therapy Elevidys, $3.2 million wholesale acquisition cost; the gene therapy Beqvez, $3.5 million; eladocagene exuparvovec-tneq, $3,950,000 U.S. wholesale acquisition cost. BioMarin announced that it will voluntarily remove Roctavian from the market, and Pfizer is ending global development and commercialization of Beqvez.
  • Payment models: Novartis' AveXis worked with payers on five-year outcomes-based pacts and pay-over-time options for Zolgensma. BioMarin offered an outcomes-based warranty for Roctavian reimbursing up to 100% of wholesale acquisition cost on a prorated basis if response is lost in the first four years, and will honor existing outcomes-based agreements after withdrawal. Pfizer launched a warranty program for Beqvez based on durability of response, and CSL Behring offered a substantial rebate for Hemgenix if patients return to prophylactic factor IX during the first 3 1/2 years. One publication on gene therapy payment groups value-based contracts into milestone-based rebates, warranties, and performance-based installment payments, and names patients changing insurers and Medicaid Best Price provisions, which apply to all value-based contracts except warranties, as barriers.
  • CMS Cell and Gene Therapy Access Model: a multi-year, voluntary model for states and manufacturers that tests a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies in Medicaid, initially focused on gene therapy for sickle cell disease, with 34 state participants and 2 manufacturer participants; states began participation between January 2025 and January 2026.

Summary: eligible population inputs and budget impact evidence

  • The report holds no budget impact model for AMT-130; every leaf of its Budget Impact Model section reads No evidence found.
  • ICER eligible population: approximately 40,000 people with Huntington's disease in the U.S. in 2020 (a prevalence rate of approximately 0.012%), approximately 62.7% of whom are in SF stage 1 or 2, applied to approximately 342 million people averaged over 2026-2030, gives 25,811 eligible patients, with 20% initiating treatment in each of the five years (5,162 patients per year). The exploratory preclinical population is 100,000 people (approximately 200,000 at risk multiplied by the 50% likelihood of inheriting the mutation), with 20,000 initiating treatment per year.
  • Prevalence and stage distribution: in a study population of 38.4 million individuals who met a continuous enrollment requirement, the prevalence rate was 6.7 per 100,000 in 2020 and 9.4 per 100,000 in 2024. In British Columbia, prevalence was 13.7 per 100,000 in the general population. In an insurance database of over 67 million enrollees, 1.18% of those diagnosed were 20 years old or less. In one study, most participants were in TFC stages I–III, with 41.3% in stage II (n = 845 in stage I, n = 1068 in stage II, n = 540 in stage III, n = 116 in stage IV, and n = 15 in stage V).
  • Other population inputs: pooled incidence was 0.48 cases per 100,000 person-years; median survival time in one cohort was 12.4 years; and in one study, 49.9% of people with Huntington's disease received neurologist care in a calendar year.
  • Budget impact method: ICER will use the placeholder price of $2,600,000 and threshold prices at $50,000 to $200,000 per evLY gained, with undiscounted costs over five years, against a potential budget impact threshold of approximately $709 million per year for 2026-2027. uniQure lists increased diagnosis due to genetic testing and disease-modifying treatment availability, and an increase in addressable patient segments, as potential long-term growth levers.
  • Reference analysis: in a CSL Behring-funded budget impact analysis of etranacogene dezaparvovec priced at $3,500,000 in a hypothetical 1-million-member plan over 5 years, 1.8 people were eligible and the cumulative budget impact was $848,509, with incremental annual costs of $79,824 to $271,435 and per-member per-month costs of $0.007 to $0.023; results were sensitive only to the uptake assumptions.

ICER model analysis plan: aim, comparator, perspective, and framework adaptations

“The primary aim of this analysis will be to estimate the cost-effectiveness of AMT-130 for HD using a Cohort Markov Model.” (opens the source at this quote in a new tab)

“The model will compare AMT-130 added onto usual symptomatic care, to usual symptomatic care alone, over a lifetime horizon.” (opens the source at this quote in a new tab)

“The base case analysis will take a health care sector perspective (i.e., focus on direct medical care costs only), and patient and caregiver productivity impacts and other indirect costs and effects will be considered in the modified societal perspective analysis.” (opens the source at this quote in a new tab)

“Scenario analyses reflecting an optimistic and conservative benefit of AMT-130.” (opens the source at this quote in a new tab)

“Threshold analysis for the durability of effect to determine the duration of beneficial effect (e.g., cure) patients receiving AMT-130 would need to achieve standard cost-effectiveness thresholds (e.g., $150,000/QALY).” (opens the source at this quote in a new tab)

“50/50 shared savings model in which 50% of lifetime health system cost offsets from AMT-130 are “assigned” to the health system instead of being entirely assigned to AMT-130.” (opens the source at this quote in a new tab)

“Cost-offset cap model in which health system cost offsets generated by AMT-130 are capped at $150,000 per year but are otherwise assigned entirely to AMT-130.” (opens the source at this quote in a new tab)

ICER model analysis plan: model structure and health states

“We will develop a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models.” (opens the source at this quote in a new tab)

“Costs and outcomes will be discounted at 3% per year.” (opens the source at this quote in a new tab)

“Model cycle length will be one year, based on what was observed in prior published economic models/clinical data.” (opens the source at this quote in a new tab)

“Health states will be defined using the Total Functional Capacity (TFC) scale, following the Shoulson and Fahn (SF) staging system” (opens the source at this quote in a new tab)

“stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 (TFC 1-2), and stage 5 (TFC 0).” (opens the source at this quote in a new tab)

“The TFC scale measures the functional ability in people with HD across five domains: occupation, finances, domestic chores, activities of daily living, and level of care required, with a score of 13 representing full/independent function and 0 representing a total loss of function.” (opens the source at this quote in a new tab)

“SF stages 1 and 2 correspond to early-stage HD, stage 3 to middle, and stages 4 and 5 to late.” (opens the source at this quote in a new tab)

“All patients will enter the model in stage 1, based on the baseline TFC reported in the pivotal trial’s primary analysis of 12.1.” (opens the source at this quote in a new tab)

“Patients remain in the model until they die.” (opens the source at this quote in a new tab)

ICER model analysis plan: serious adverse event rates and costs

EventRateCost
Peri-operative SAE“16.4%”“$10,645”
Peri-operative SAE component: post-lumbar puncture syndrome“22.2%”“$10,351”
Treatment-related SAE“19.2%”“$19,501”

ICER methods for single and short-term therapies: definition, shared savings, and durability threshold

“therapies that are delivered through a single intervention or a short-term course (less than one year) of treatment that offer a significant potential for substantial and sustained health benefits extending throughout patients’ lifetimes.” (opens the source at this quote in a new tab)

“A 50/50 shared savings model in which 50% of the lifetime health system cost offsets from a new treatment are “assigned” to the health system instead of being assigned entirely to the new treatment; and” (opens the source at this quote in a new tab)

“A cost-offset cap model in which the health system cost offsets generated by a new treatment are capped at $150,000 per year but are otherwise assigned entirely to the new treatment.” (opens the source at this quote in a new tab)

“The figure of $150,000 is being selected because it is at the top of the ICER range for value-based pricing for an additional QALY.” (opens the source at this quote in a new tab)

“This threshold analysis may also help inform the time horizon for outcomes-based contracts should payers and manufacturers wish to use a cost-effectiveness threshold as a target for establishing fair value.” (opens the source at this quote in a new tab)

“We will also add caveats to these analyses noting that they may not be applicable in situations where there are outcomes-based contracts or other risk-sharing arrangements in place that are not included within these analyses.” (opens the source at this quote in a new tab)

Payment models for gene therapy: value-based contracts, warranties, and short-term budget impact for U.S. payers

“Value-based contracts fall broadly into three categories: milestone-based rebates, warranties and performance-based installment payments (sometimes referred to as an annuity).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“First, patients treated with gene therapies may change insurers during the term of any payment contract, greatly complicating efforts to track outcomes and link them to additional rebates, a warranty, or performance-based installment payments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A third barrier, Medicaid Best Price (MBP) provisions, applies to all value-based contracts except warranties” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For example, Roctavian™ launched with an outcomes-based warranty offered to all US insurers, which will reimburse payers on a pro-rated basis over the first 4 years from the time of dosing if the patient loses response – up to 100% of wholesale acquisition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For these payers, an unpredictable $1–3 million treatment may be such a large percentage of their annual health costs that an upfront payment would be financially destabilizing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All told, 85 new gene therapies across more than 12 therapeutic areas are expected to receive regulatory approval by 2032, with an estimated ten-year list price spend of $35 to $40 billion” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Budget impact of etranacogene dezaparvovec in a hypothetical 1-million-member health plan, funded by CSL Behring

“The model considered a hypothetical 1-million-member plan over a 5-year horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the 1-million-member health plan, an estimated 1.8 PwHB were eligible for treatment with etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Gradual uptake of etranacogene dezaparvovec resulted in cumulative 5-year budget impact of $848,509 compared with a scenario without etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In years 1-5, the incremental annual and per-member per-month costs ranged from $79,824 to $271,435 and from $0.007 to $0.023, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Etranacogene dezaparvovec price was assumed to be $3,500,000 as a single administration (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the analysis assuming 100% uptake of etranacogene dezaparvovec in year 1, incremental annual cost of $4.843 million (Figure 2A) or $0.40 PMPM” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Scenario analyses (Table 3) showed that the 5-year budget impact results were sensitive only to the assumptions regarding uptake of etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was conducted by RTI Health Solutions and funded by CSL Behring LLC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

U.S. cost-effectiveness analysis of tominersen and AMT-130 in early-stage HD

U.S. cost-effectiveness analysis of tominersen and AMT-130: model structure, perspective, and time horizon

“A modified societal perspective was adopted to capture direct healthcare costs and non-healthcare costs such as caregiver burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The cycle length was 1 year with an annual discount rate of 3% used for all future costs and utilities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“a total of 30 annual cycles were considered sufficient to capture lifetime costs and health outcomes associated with the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All patients entered the model in the early stage, and at the end of each cycle, they could transition into a different health stage, stay in the early stage, or experience death” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For Tominersen, we postulated that even though the drug would result in slowing the disease progression, it would not result in disease reversal. Therefore, we made an assumption on the basis of expert opinion that the probability of disease progression from the early stage to the middle stage would reduce from 0.16 to 0.1 for the base-case model” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Utilities for Tominersen and AMT-130 were assumed equal to SoC because trial-based utility data are not yet available.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

U.S. cost-effectiveness analysis: standard of care inputs by disease stage

InputBase caseRange
Transition probability, early to middle“0.16”View highlighted excerpt for this quote“0.1–0.2”View highlighted excerpt for this quote
Transition probability, middle to late“0.32”View highlighted excerpt for this quote“0.3–0.4”View highlighted excerpt for this quote
Mortality rate, early to death“0.01”View highlighted excerpt for this quote“0–0.05”View highlighted excerpt for this quote
Mortality rate, middle to death“0.03”View highlighted excerpt for this quote“0–0.05”View highlighted excerpt for this quote
Mortality rate, late to death“0.1”View highlighted excerpt for this quote“0–0.15”View highlighted excerpt for this quote
Early stage, inpatient cost“$1067”View highlighted excerpt for this quote“$1044–1091”View highlighted excerpt for this quote
Early stage, outpatient cost“$3962”View highlighted excerpt for this quote“$3878–4047”View highlighted excerpt for this quote
Early stage, pharmacy cost“$11,124”View highlighted excerpt for this quote“$10,705–11,544”View highlighted excerpt for this quote
Early stage, caregiver cost“$6120”View highlighted excerpt for this quote“$6117–6124”View highlighted excerpt for this quote
Middle stage, inpatient cost“$4492”View highlighted excerpt for this quote“$4456–4528”View highlighted excerpt for this quote
Middle stage, outpatient cost“$10,356”View highlighted excerpt for this quote“$10,293–10,420”View highlighted excerpt for this quote
Middle stage, pharmacy cost“$13,001”View highlighted excerpt for this quote“$12,633–13,370”View highlighted excerpt for this quote
Middle stage, caregiver cost“$38,380”View highlighted excerpt for this quote“$33,756–43,004”View highlighted excerpt for this quote
Late stage, inpatient cost“$19,188”View highlighted excerpt for this quote“$18,933–19,444”View highlighted excerpt for this quote
Late stage, outpatient cost“$17,942”View highlighted excerpt for this quote“$17,621–18,263”View highlighted excerpt for this quote
Late stage, pharmacy cost“$19,283”View highlighted excerpt for this quote“$18,909–19,657”View highlighted excerpt for this quote
Late stage, caregiver cost“$112,287”View highlighted excerpt for this quote“$82,119–142,454”View highlighted excerpt for this quote
Utility, early stage“0.73”View highlighted excerpt for this quote“0.7–0.9”View highlighted excerpt for this quote
Utility, middle stage“0.63”View highlighted excerpt for this quote“0.5–0.7”View highlighted excerpt for this quote
Utility, late stage“0.57”View highlighted excerpt for this quote“0.4–0.6”View highlighted excerpt for this quote

U.S. cost-effectiveness analysis: drug price and administration cost assumptions

U.S. cost-effectiveness analysis: scenario and sensitivity analyses

“After considering the additional value of hope to the base-case utility value, the total QALYs for Tominersen increased from 7.03 to 7.49, and for AMT-130, it increased from 11.34 to 12.43.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As a result, the ICER value decreased significantly from $2.28 million per QALY gained to $1.52 million per QALY gained for Tominersen, and for AMT-130, it changed from $285,703 per QALY gained to $236,540 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“One-way sensitivity analyses indicated that the ICERs were most sensitive to the cost of the drugs, particularly AMT-130 and Tominersen, as well as health-state utility values for early and middle-stage HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The cost-effectiveness acceptability curve revealed that the probability of AMT-130 being considered cost-effective at a WTP threshold of $250,000 per QALY gained was 30%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The probability of Tominersen being considered cost-effective was 0% throughout the curve” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Findings from the PSA also indicated that the probability of both of the treatments being considered cost-effective was 0% at the conventional WTP threshold of $100,000–150,000 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Health technology assessment: ICER draft scope for population, comparator, and planned models